Saffron- based crocin prevents early lesions of liver cancer: In vivo, in vitro and Network analyses

Recent Patents on Anti-Cancer Drug Discovery

Volumn 11, Issue 1, 2016, Pages 121-133

  Amin, Amr ^a,b   Hamza, Alaaeldin A ^c   Daoud, Sayel ^d   Khazanehdari, Kamal ^e   Al Hrout, Ala’a ^a   Baig, Badriya ^a   Chaiboonchoe, Amphun ^f   Adrian, Thomas E ^a   Zaki, Nazar ^a   Salehi Ashtiani, Kourosh ^f  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b CAIRO UNIVERSITY   (Egypt)

^c NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

^d TAWAM HOSPITAL   (United Arab Emirates)

^e Molecular Biology and Genetics Laboratory   (United Arab Emirates)

^f NEW YORK UNIVERSITY ABU DHABI   (United Arab Emirates)

Author keywords

Apoptosis; Crocin; Inflammation; Liver cancer; Network analysis; NF B

Indexed keywords

CHEMOKINE RECEPTOR CCR6; CROCIN; GLUTATHIONE TRANSFERASE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; KI 67 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; CAROTENOID; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE ASSOCIATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; NETWORK ANALYSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PRO APOPTOTIC ACTIVITY; PROTEIN EXPRESSION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CROCUS; DRUG EFFECTS; GENE REGULATORY NETWORK; HEP-G2 CELL LINE; LIVER NEOPLASMS; METABOLISM; PATENT; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CAROTENOIDS; CROCUS; GENE REGULATORY NETWORKS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PATENTS AS TOPIC; RATS; RATS, WISTAR;

EID: 84958962621     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892810666151102110248     Document Type: Article

References (67)

1. Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11. Available at: http: //globocan. iarc. fr (Accessed on: January 4, 2015).
2. Sherman M. Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Seminar in Liver Disease 2010; 30(1): 3-16.
3. Nahon P, Ganne-Carrié N, Trinchet J-C, Beaugrand M. Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis. Gastroenterol Clin Biol 2010; 34(1): 1-7.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010; 51(5): 1820-32.
5. Park D-H, Shin JW, Park S-K, Seo J-N, Li L, Jang J-J, et al. Diethylnitrosamine (DEN) induces irreversible hepatocellular carcinogenesis through overexpression of G1/S-phase regulatory proteins in rat. Toxicol Lett 2009; 191(2-3): 321-6.
6. Wang Y-H, Cheng T-Y, Chen T-Y, Chang K-M, Chuang VP, Kao K-J. Plasmalemmal Vesicle Associated Protein (PLVAP) as a therapeutic target for treatment of hepatocellular carcinoma. BMC Cancer 2014; 14: 815.
7. Bupathi M, Kaseb A, Meric-Bernstam F, Naing A. Hepatocellular carcinoma: Where there is unmet need. Mol Oncol 2015; 9(8): 1501-9.
8. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 2015; 16. pii: S1044-579X(15) 00002-4.
9. Eldehna WM, Fares M, Ibrahim HS, Aly MH, Zada S, Ali MM, et al. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking. Eur J Med Chem 2015; 100: 89-97.
10. Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010; 16(14): 3548-61.
11. Alam, A., Blanc, I. Use of VEGFR3 inhibitors for treating hepatocellular carcinoma. US20150183780 (2015).
12. Herrnberger L, Hennig R, Kremer W, Hellerbrand C, Goepferich A, Kalbitzer HR, et al. Formation of fenestrae in murine liver sinusoids depends on plasmalemma vesicle-associated protein and is required for lipoprotein passage. PLoS One 2014; 9(12): e115005.
13. Kao, K-J., Wang, Y. H. Therapeutic biologic for treatment of hepatocellular carcinoma. KR20140159041 (2014).
14. Kao, K., Huang, A. T. Methods and agents for the diagnosis and treatment of hepatocellular carcinoma. TW20150103866 (2015).
15. Kao, K., Huang, A. T. Monoclonal antibodies and proteins that specifically bind PLVAP, and compositions containing, and uses, of the same for the diagnosis and treatment of hepatocellular carcinoma. TW20140140971 (2015).
16. Gong B, Hu H, Chen J, Cao S, Yu J, Xue J, et al. Caprin-1 is a novel microRNA-223 target for regulating the proliferation and invasion of human breast cancer cells. Biomed Pharmacother 2013; 67(7): 629-36.
17. Saito, T., Okano, F., Ido, T., Minamida, Y. Pharmaceutical composition for treatment and/or prevention of liver cancer. US201314389266 (2015).
18. Kumada, H., Muto, Y., Sato, S., Watanabe, A. Inhibitor for the onset and progress of liver cancer to be used in hepatitis C viruspositive human liver cirrhosis patients. KR20157011367 (2015).
19. Mishra CB, Kumari S, Tiwari M. Thiazole: A promising heterocycle for the development of potent CNS active agents. Eur J Med Chem 2015; 92: 1-34.
20. Cuconati, A., Xiaodong, X., Block, T. M. Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication. HK20150101053 (2015).
21. Friese, H. M., Bladt, F. A 6oxo1, 6dihydropyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC). KR20157014482 (2015).
22. Block K, Gyllenhaal C, Lowe L, Amedei A, Amin AMR, Amin A, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 2015; 35: S276-304.
23. Vijaya BK. Medicinal uses and pharmacological properties of Crocus sativus linn (saffron). Int J Pharm Pharmaceutical Sci 2011; 3(3): 22-6.
24. Das I, Das S, Saha T. Saffron suppresses oxidative stress in DMBA-induced skin carcinoma: A histopathological study. Acta Histochem 2010; 112(4): 317-27.
25. Javadi B, Sahebkar A, Emami SA. A survey on saffron in major islamic traditional medicine books. Iran J Basic Med Sci 2013; 16(1): 1-11.
26. Noureini SK, Wink M. Antiproliferative effects of crocin in HepG2 cells by telomerase inhibition and hTERT down-regulation. Asian Pacific J Cancer Prev 2012; 13(5): 2305-9.
27. Hoshyar R, Bathaie SZ, Sadeghizadeh M. Crocin triggers the apoptosis through increasing the Bax/Bcl-2 ratio and caspase activation in human gastric adenocarcinoma, AGS, cells. DNA Cell Biol 2013; 32(2): 50-7.
28. Bajbouj K, Schulze-Luehrmann J, Diermeier S, Amin A, Schneider-Stock R. The anticancer effect of saffron in two p53 isogenic colorectal cancer cell lines. BMC Complementary Alternat Med 2012; 12: 69.
29. Amin A, Hamza AA, Bajbouj K, Ashraf SS, Daoud S. Saffron: A potential candidate for a novel anticancer drug against hepatocellular carcinoma. Hepatology 2011; 54(3): 857-67.
30. Chung, Y., Siu, M., Lai, T., Yeh, S. Plant extract and the process for treating hepatic fibrosis and liver cancer. US201514144264 (2015).
31. Bannasch P, Haertel T, Su Q. Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol Pathol 2003; 31(1): 134-9.
32. Li X, Zhou XP, Guan YS, Wang YXJ. Magnetic resonance imaging of hepatocellular carcinoma induced by diethylnitrosamine in sprague-dawley rats. Hepatobiliary Pancreat Dis Int 2005; 4(3): 427-32.
33. Espandiari P, Robertson LW, Srinivasan C, Glauert HP. Comparison of different initiation protocols in the resistant hepatocyte model. Toxicology 2005; 206(3): 373-81.
34. Hariri AT, Moallem SA, Mahmoudi M, Hosseinzadeh H. The effect of crocin and safranal, constituents of saffron, against subacute effect of diazinon on hematological and genotoxicity indices in rats. Phytomedicine 2011; 18(6): 499-504.
35. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9. 1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41(D1).
36. Sakai M, Muramatsu M. Regulation of glutathione transferase P: A tumor marker of hepatocarcinogenesis. Biochem Biophys Res Commun 2007; 357(3): 575-8.
37. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25(1): 25-9.
38. Tew KD, Manevich Y, Grek C, Xiong Y, Uys J, Townsend DM, et al. The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radic Biol Med 2011; 51(2): 299-313.
39. Townsend DM, Findlay VL, Tew KD. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol 2005; 401: 287-307.
40. Dragan YP, Hully J, Crow R, Mass M, Pitot HC. Incorporation of bromodeoxyuridine in glutathione S-transferase-positive hepatocytes during rat multistage hepatocarcinogenesis. Carcinogenesis 1994; 15(9): 1939-47.
41. Samadi AK, Georgakilas AG, Amedei A, Amin A, Bishayee A, Lokeshwar BL, et al. A multi-targeted approach to suppress tumorpromoting inflammation. Semin Cancer Biol 2015; 10. 1016/j. semcancer. 2015. 03. 006.
42. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: A new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm 2008; 2008: 135625.
43. Kern MA, Schirmacher P, Breinig M. Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma. Verh Dtsch Ges Pathol 2007; 91: 257-68.
44. Luedde T, Schwabe RF. NF-κB in the liver linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8(2): 108-18.
45. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001; 480-481: 243-68.
46. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJJ. Interleukin-8 signaling attenuates TRAIL-and chemotherapyinduced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008; 7(9): 2649-61.
47. Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D, et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 2012; 106(11): 1833-41.
48. Waugh DJJ, Wilson C. The interleukin-8 pathway in cancer. Clinical Canc Res 2008; 14(21): 6735-41.
49. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: Can we interpret the code? Molecular Oncol 2012; 6(6): 637-56.
50. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Letters 2009; 280(2): 168-76.
51. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007; 72(1-2): 69-74.
52. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6(1): 38-51.
53. Karagiannis TC, El-Osta A. Chromatin modifications and DNA double-strand breaks: the current state of play. Leuk Off J Leuk Soc Am Leuk Res Fund, UK. 2007; 21(2): 195-200.
54. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003; 10(4): 400-3.
55. Glauben R, Sonnenberg E, Zeitz M, Siegmund B. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Letters 2009; 280(2): 154-9.
56. Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NFkB activation by suppressing proteasome activity: Down-regulation of proteasome subunit expression stabilizes IkB alpha Biochem Pharmacol 2005; 70(3): 394-406.
57. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factorkappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006; 66(10): 5409-18.
58. Sugita S, Kohno T, Yamamoto K, Imaizumi Y, Nakajima H, Ishimaru T, et al. Induction of macrophage-inflammatory protein-3alpha gene expression by TNF-dependent NF-kappaB activation. J Immunol 2002; 168(11): 5621-8.
59. Yang CC, Ogawa H, Dwinell MB, McCole DF, Eckmann L, Kagnoff MF. Chemokine receptor CCR6 transduces signals that activate p130Cas and alter cAMP-stimulated ion transport in human intestinal epithelial cells. Am J Physiol Cell Physiol 2005; 288(2): C321-8.
60. Ghadjar P, Coupland SE, Na I-K, Noutsias M, Letsch A, Stroux A, et al. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 2006; 24(12): 1910-6.
61. Rubie C, Oliveira V, Kempf K, Wagner M, Tilton B, Rau B, et al. Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumor Biol 2006; 27(3): 166-74.
62. Rubie C, Frick VO, Wagner M, Rau B, Weber C, Kruse B, et al. Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand J Immunol 2006; 63(6): 468-77.
63. kB signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503. PLoS One 2013; 8(5): e65153.
64. Matsumiya T, Ota K, Imaizumi T, Yoshida H, Kimura H, Satoh K. Characterization of synergistic induction of CX3CL1/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF-alpha in post-transcriptional regulation of CX3CL1. J. Immunol. 2010; 184: 4205-4214.
65. Sans M, Danese S, de la Motte C, de Souza HSP, Rivera-Reyes BM, West GA, et al. Enhanced Recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology 2007; 132(1): 139-53.
66. Yao X, Qi L, Chen X, Du J, Zhang Z, Liu S. Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma. Urol Oncol Semin Orig Investig 2014; 32(2): 162-70.
67. Efsen E, Grappone C, DeFranco RMS, Milani S, Romanelli RG, Bonacchi A, et al. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 2002; 37(1): 39-47.